Antioxidant profile of hyaluronan: Physico-chemical features and its role in pathologies

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 13, 2009, Pages 1479-1488

  Mendoza, G ^a   Prieto, J G ^a   Real, R ^a   Perez M ^a   Merino, G ^a   Alvarez A I ^a  

^a UNIVERSITY OF LEÓN   (Spain)

Author keywords

Antioxidants; Hyaluronan; Inflammation; Oxidative damage; Reactive oxygen species; Therapeutic use

Indexed keywords

4 HYDROXYBENZOIC ACID; ACETYLSALICYLIC ACID; DEFEROXAMINE; HISTIDINE; HYALURONIC ACID; IBUPROFEN; LIDOCAINE; MANNITOL; NAPROXEN; PARACETAMOL; PENICILLAMINE; PROPOFOL; SALICYLIC ACID; SCAVENGER; STOBADINE; THIOUREA; VINPOCETINE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CELL DAMAGE; ENZYME DEGRADATION; IN VITRO STUDY; IN VIVO STUDY; OXIDATIVE STRESS; PHYSICAL CHEMISTRY; SHORT SURVEY;

ANIMALS; ANTIOXIDANTS; HUMANS; HYALURONIC ACID;

EID: 75449096588     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709790361494     Document Type: Short Survey

References (104)

1. Garg, H.G.; Hales, C.A. Chemistry and Biology of Hyaluronan; Elsevier Ltd, Amsterdam, 2004.
2. Stern, R.; Kogan, G.; Jedrzejas, M.J.; Šoltés, L. The many ways to cleave hyaluronan. Biotechnol., Adv., 2007, 25, 537-57.
3. Moseley, R.; Leaver, M.; Walker, M.; Waddington, R.J.; Parsons, D.; Chen, W.Y.J.; Embery, G. Comparison of the antioxidant properties of HYAFF® -11p75, AQUACEL® and hyaluronan towards reactive oxygen species in vitro. Biomaterials, 2002, 23, 2255-64.
4. Girish, K.S.; Kemparaju, K. The magic glue hyaluronan and its eraser hyaluronidase: a biological overview. Life Sci., 2007, 80, 1921-43.
5. Almond, A.; DeAngelis, P.L.; Blundell, C.D. Hyaluronan: the local solution conformation determined by NMR and computer modeling is close to a contracted left-handed 4-fold helix. J. Mol. Biol., 2006, 358, 1256-69.
6. Gura, E.; Hückel, M.; Müller, P.J. Specific degradation of rheological hyaluronic acid and its properties. Polym. Degrad. Stabil., 1997, 59, 297-302.
7. Almond, A. Visions & Reflections (Minireview). Hyaluronan. Cell. Mol. Life Sci., 2007, 64, 1591-6.
8. Cowman, M.K.; Matsuoka, S. Experimental approaches to hyaluronan structure. Carbohydr. Res., 2005, 340, 791-809.
9. Lepperdinger, G.; Fehrer, C.; Reitinger, S. In Chemistry and biology of hyaluronan; Elsevier Ltd, Amsterdam, 2004; pp. 71-82.
10. Flugge, L.A.; Miller-Deist, L.A.; Petillo, P.A. Towards a molecular understanding of arthritis. Chem. Biol., 1999, 6, R157-66.
11. Yamawaki. H.; Hirohata, S.; Miyoshi, T.; Takahashi, K.; Ogawa, H.; Shinohata, R.; Demircan, K.; Kusachi, S.; Yamamoto, K.; Ninomiya, Y. Hyaluronan receptors involved in cytokine induction in monocytes. Glycobiology, 2009, 19, 83-92.
12. Halliwell, B.; Whiteman, M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br. J. Pharmacol., 2004, 142, 231-55.
13. Young, I.S.; Woodside, J.V. Antioxidants in health and disease. J. Clin. Pathol., 2001, 54, 176-86.
14. Šoltés, L.; Stankovská, M.; Kogan, G.; Gemeiner, P.; Stern, R. Contribution of oxidative-reductive reactions to high-molecular- weight hyaluronan catabolism. Chem. Biodivers., 2005, 2, 1242-5.
15. Rees, M.D.; Hawkins, C.L.; Davies, M.J. Hypochlorite and superoxide radicals can act synergistically to induce fragmentation of hyaluronan and chondroitin sulphates. Biochem. J., 2004, 381, 175-84.
16. Bergendi, L.; Beneš , L.; Ďuračková, Z.; Feren ik, M. Chemistry, physiology and pathology of free radicals. Life Sci., 1999, 65, 1865-74.
17. Schiller, J.; Fuchs, B.; Arnhold, J.; Arnold, K. Contribution of reactive oxygen species to cartilage degradation in rheumatic diseases: molecular pathways, diagnosis and potential therapeutic strategies. Curr. Med. Chem., 2003, 10, 2123-45.
18. Šoltés, L.; Valachová, K.; Mendichi, R.; Kogan, G.; Arnhold, J.; Gemeiner, P. Solution properties of high-molar-mass hyaluronans: the biopolymer degradation by ascorbate. Carbohydr. Res., 2007, 342, 1071-7.
19. Halliwell, B.; Gutteridge, J.M.C. In: Free Radicals in Biology and Medicine; Oxford University Press: UK, 1999; p. 106.
20. Saari, H.; Konttinen, Y.T.; Friman, C.; Sorsa, T. Differential effects of reactive oxygen species on native synovial fluid and purified human umbilical cord hyaluronate. Inflammation, 1993, 17, 403-15.
21. Balogh, G.T.; Illés, J.; Székely, Z.; Forrai, E.; Gere, A. Effect of different metal ions on the oxidative damage and antioxidant capacity of hyaluronic acid. Arch. Biochem. Biophys., 2003, 410, 76-82.
22. Moseley, R.; Walker, M.; Waddington, R.J.; Chen, W.Y.J. Comparison of the antioxidant properties of wound dressing materials - carboxymethylcellulose, hyaluronan benzyl ester and hyaluronan, towards polymorphonuclear leukocyte-derived reactive oxygen species. Biomaterials, 2003, 24, 1549-57.
23. Trommer, H.; Wartewig, S.; Böttcher, R.; Pöppl, A.; Hoentsch, J.; Ozegowski, J.H.; Neubert, R.H.H. The effects of hyaluronan and its fragments on lipid models exposed to UV irradiation. Int. J. Pharm., 2003, 254, 223-34.
24. Halliwell, B. Superoxide-dependent formation of hydroxyl radicals in the presence of iron salts. Its role in degradation of hyaluronic acid by a superoxide-generating system. FEBS Lett., 1978, 96, 238-42.
25. Paimela, L.; Heiskanen, A.; Kurki, P.; Helve, T.; Leirisalo-Repo, M. Serum hyaluronate level as a predictor of radiologic progression in early rheumatoid arthritis. Arthritis Rheum., 1991, 34, 815-21.
26. Laurent, T.C.; Laurent, U.B.; Fraser, J.R. Serum hyaluronan as a disease marker. Ann. Med., 1996, 28, 241-53.
27. Moseley, R.; Waddington, R.J.; Embery, G. Degradation of glycosaminoglycans by reactive oxygen species derived from stimulated polymorphonuclear leukocytes. Biochem. Biophys. Acta., 1997, 1362, 221-31.
28. Tishler, M.; Yaron, I.; Shirazi, I.; Yaron, M. Salivary and serum hyaluronic acid concentrations in patients with Sjögren's syndrome. Ann. Rheum. Dis., 1998, 57, 506-8.
29. McHutchison; J.G.; Blatt, L.M.; de Medina, M.; Craig, J.R.; Conrad, A.; Schiff, E.R.; Tong, M.J. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J. Gastroenterol. Hepatol., 2000, 15, 945-51.
30. Woollard, A.C.S.; Wolff, S.P.; Bascal, Z.A. Antioxidant characteristics of some potential anticataract agents. Studies of aspirin, paracetamol, and bendazac provide support for an oxidative component of cataract. Free Radic. Biol. Med., 1990, 9, 299-305.
31. Presti, D.; Scott, J.E. Hyaluronan-mediated protective effect against cell damage caused by enzymatically produced hydroxyl radicals is dependent on hyaluronan molecular mass. Cell Biochem. Funct., 1994, 12, 281-288.
32. Kvam, B.J.; Fragonas, E.; Degrassi, A.; Kvam, C.; Matulova, M.; Pollesello, P.; Zanetti, F.; Vittur, F. Oxygen-derived free radical (ODFR) action on hyaluronan (HA), on two HA ester derivatives, and on the metabolism of articular chondrocytes. Exp. Cell Res., 1995, 218, 79-86.
33. Cortivo, R.; Brun, P.; Cardarelli, L.; O'Regan, M.; Radice, M.; Abatangelo, G. Antioxidant effects of hyaluronan and its α-methyl- prednisolone derivative in chondrocyte and cartilage cultures. Semin. Arthritis Rheum., 1996, 26, 492-501.
34. Ialenti, A.; Di Rosa, M. Hyaluronic acid modulates acute and chronic inflammation. Agents Actions, 1994, 43, 44-7.
35. Venge, P.; Pedersen, B.; Håkansson, L.; Hällgren, R.; Lindblad, G.; Dahl, R. Subcutaneous administration of hyaluronan reduces the number of infectious exacerbations in patients with chronic bronchitis. Am. J. Respir. Crit. Care Med., 1996, 153, 312-6.
36. Sakurai, K.; Andoh, M.; Yamada, M.; Kodera, Y.; Nishimura, H.; Hiroto, M.; Matsushima, A.; Aoyama, M.; Yamamoto, H.; Inada, Y. Suppression of ischemic edema in mice by manganese-hyaluronate conjugate. Jpn. J. Pharmacol., 1997, 74, 117-20.
37. Zeng, C.; Toole, B.P.; Kinney, S.D.; Kuo, J.W.; Stamenkovic, I. Inhibition of tumor growth in vivo by hyaluronan oligomers. Int. J. Cancer, 1998, 77, 396-401.
38. Dougados, M. Sodium hyaluronate therapy in osteoarthritis: arguments for a potential beneficial structural effect. Semin. Arthritis Rheum., 2000, 30, 19-25.
39. Al-Assaf, S.; Phillips, G.O.; Deeble, D.J.; Parsons, B.; Starnes, H.; Von Sonntag, C. The enhanced stability of the cross-linked hylan structure to hydroxyl radicals compared with the uncrosslinked hyaluronan. Radic. Phys. Chem., 1995, 46, 207-17.
40. Maugeri, F.; Maltese, A.; Ward, K.W.; Bucolo, C. Hydroxyl radical scavenging activity of a new ophthalmic viscosurgical device. Curr. Eye Res., 2007, 32, 105-11.
41. Halliwell, B. Antioxidants in human health and disease. Annu. Rev. Nutr., 1996, 16, 33-50.
42. Lindvall, S.; Rydell, G. Influence of various compounds on the degradation of hyaluronic acid by a myeloperoxidase system. Chem. Biol. Interact., 1994, 90, 1-12.
43. Li, M.; Rosenfeld, L.; Vilar, R.E.; Cowman, M.K. Degradation of hyaluronan by peroxynitrite. Arch. Biochem. Biophys., 1997, 341, 245-50.
44. Orviský, E.; Šoltés, L.; Stančí ková, M. High-molecular-weight hyaluronan - a valuable tool in testing the antioxidative activity of amphiphilic drugs stobadine and vinpocetine. J. Pharm. Biomed. Anal., 1997, 16, 419-24.
45. Belda, J. I.; Artola, A.; García-Manzanares, M. D.; Ferrer, C.; Haroun, H. E.; Hassanein, A.; Baeyens, V.; Muñoz, G.; Alió, J. L. Hyaluronic acid combined with mannitol to improve protection against free-radical endothelial damage: experimental model. J. Cataract. Refract. Surg., 2005, 31, 1213-8.
46. Mendoza, G.; Álvarez, A.I.; Pulido, M.M.; Molina, A.J.; Merino, G.; Real, R.; Fernandes, P.; Prieto, J.G. Inhibitory effects of different antioxidants on hyaluronan depolymerization. Carbohydr. Res., 2007, 342, 96-102.
47. Kvam, C.; Granese, D.; Flaibani, A.; Pollesello, P.; Paoletti, S. Hyaluronan can be protected from free-radical depolymerisation by 2,6-diisopropylphenol, a novel radical scavenger. Biochem. Biophys. Res. Commun., 1993, 193, 927-33.
48. Valachová, K.; Hrabarova, E.; Gemeiner, P.; Šoltés, L. Study of pro- and anti-oxidative properties of D-penicillamine in a system comprising high-molar-mass hyaluronan, ascorbate, and cupric ions. Neuro. Endocrinol. Lett., 2008, 29, 697-701.
49. Gao, F.; Koenitzer, J.R.; Tobolewski, J.M.; Jiang, D.; Liang, J.; Noble, P.W.; Oury, T.D. Extracellular superoxide dismutase inhibits inflammation by preventing oxidative fragmentation of hyaluronan. J. Biol. Chem., 2008, 283, 6058-66.
50. Šoltés, L.; Stankovská, M.; Kogan, G.; Mendichi, R.; Volpi, N.; Sasinková, V.; Gemeiner, P. Degradation of high-molar-mass hyaluronan by an oxidative system comprising ascorbate, Cu(II), and hydrogen peroxide: inhibitory action of antiinflammatory drugs - naproxen and acetylsalicylic acid. J. Pharm. Biomed. Anal., 2007, 44, 1056-63.
51. Šoltés, L.; Lath, D.; Mendichi, R.; Bystrický, P. Radical degradation of high molecular weight hyaluronan: inhibition of the reaction by ibuprofen enantiomers. Methods Find Exp. Clin. Pharmacol., 2001, 23, 65-71.
52. Stern, R.; Asari, A.A.; Sugahara, K.N. Hyaluronan fragments: an information-rich system. Eur. J. Cell Biol., 2006, 85, 699-715.
53. Kennett, E.C.; Davies, M.J. Glycosaminoglycans are fragmented by hydroxyl, carbonate, and nitrogen dioxide radicals in a site-selective manner: implications for peroxynitrite-mediated damage at sites of inflammation. Free Radic. Biol. Med., 2009, 47, 389-400.
54. Šoltés, L.; Valachová, K.; Mendichi, R.; Kogan, G.; Arnhold, J.; Gemeiner, P. Solution properties of high-molar-mass hyaluronans: the biopolymer degradation by ascorbate. Carbohydr. Res., 2007, 342, 1071-7.
55. Albertini, R.; Passi, A.; Abuja, P.M.; De Luca, G. The effect of glycosaminoglycans and proteoglycans on lipid peroxidation. Int. J. Mol. Med., 2000, 6, 126-36.
56. Campo, G.M.; Avenoso, A.; Campo, S.; Ferlazzo, A.M.; Altavilla, A.; Calatroni, A. Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats. Arthritis Res. Ther., 2003, 5, R122-31.
57. Campo, G.M.; Avenoso, A.; Campo, S.; Ferlazzo, A.M.; Altavilla, D.; Micali, C.; Calatroni, A. Aromatic trap analysis of free radicals production in experimental collagen-induced arthritis in the rat: protective effect of glycosaminoglycans treatment. Free Radic. Res., 2003, 37, 257-68.
58. Balazs, E.A. Viscosupplementation for treatment of osteoarthritis: from initial discovery to current status and results. Surg. Technol. Int., 2004, 12, 278-89.
59. Halicka, H.D.; Mitlitski, V.; Heeter, J.; Balazs, E.A.; Darzynkiewicz, Z. Attenuation of the oxidative burst-induced DNA damage in human leukocytes by hyaluronan. Int. J. Mol. Med., 2009, 23, 695-9.
60. Zhou, P.H.; Liu, S.Q.; Peng, H. The effect of hyaluronic acid on IL-1β-induced chondrocyte apoptosis in a rat model of osteoarthritis. J. Orthop. Res., 2008, 26, 1643-8.
61. 2) in human fibroblast cultures. Glycoconjug. J., 2004, 20, 133-41.
62. Fukuda, K.; Oh, M.; Asada, S.; Hara, F.; Matsukawa, M.; Otani, K.; Hamanishi, C. Sodium hyaluronate inhibits interleukin-1-evoked reactive oxygen species of bovine articular chondrocytes. Osteoarthritis Cartilage, 2001, 9, 390-2.
63. Zhao, H.; Tanaka, T.; Mitlitski, V.; Heeter, J.; Balazs, E.A.; Darzynkiewicz, Z. Protective effect of hyaluronate on oxidative DNA damage in WI-38 and A549 cells. Int. J. Oncol., 2008, 32, 1159-67.
64. Stambrook, P.J. An ageing question: do embryonic stem cells protect their genomes? Mech. Ageing Dev., 2007, 128, 31-5.
65. Sales, K.M.; Winslet, M.C.; Seifalian, A. Stem cells and cancer: an overview. Stem Cell Rev., 2007, 3, 249-55.
66. Reeijmakers, M.H.G.P. ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutic targets in acute and chronic myeloid leukemia. Leukemia, 2007, 21, 2094-102.
67. Kogan, G.; Šoltés, L.; Stern, R.; Gemeiner, P. Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications. Biotechnol. Lett., 2007, 29, 17-25.
68. Tanimoto, K.; Ohno, S.; Fujimoto, K.; Honda, K.; Ijuin, C.; Tanaka, N.; Doi, T.; Nakahara, M.; Tanne, K. Proinflammatory cytokines regulate the gene expression of hyaluronic acid synthetase in cultured rabbit synovial membrane cells. Connect Tissue Res., 2001, 42, 187-95.
69. Saari, H. Oxygen derived free radicals and synovial fluid hyaluronate. Ann. Rheum. Dis., 1991, 50, 389-92.
70. de la Motte, C.; Nigro, J.; Vasanji, A.; Rho, H.; Kessler, S.; Bandyopadhyay, S.; Danese, S.; Fiocchi, C.; Stern, R. Platelet-derived hyaluronidase 2 cleaves hyaluronan into fragments that trigger monocyte-mediated production of proinflammatory cytokines. Am. J. Pathol., 2009, 174, 2254-64.
71. Smith, M.M.; Ghosh, P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Rheumatol. Int., 1987, 7, 113-22.
72. Moreland, L.W. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Res. Ther., 2003, 5, 54-67.
73. Comer, J.S.; Kincaid, S.A.; Baird, A.N.; Kammermann, J.R.; Hanson, R.R.; Ogawa, Y. Immunolocalization of stromelysin, tumor necrosis factor (TNF) alpha, and TNF receptors in atrophied canine articular cartilage treated with hyaluronic acid and transforming growth factor beta. Am. J. Vet. Res., 1996, 57, 1488-96.
74. Takahashi, K.; Goomer, R.S.; Harwood, F.; Kubo, T.; Hirasawa, Y.; Amiel, D. The effects of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin-1beta (IL-1beta), and tissue inhibitor of metalloproteinase-1 (TIMP-1) gene expression during the development of osteoarthritis. Osteoarthritis Cartilage, 1999, 7, 182-90.
75. Yasui, T.; Akatsuka, M.; Tobetto, K.; Umemoto, J.; Ando, T.; Yamashita, K.; Hayakawa, T. Effects of hyaluronan on the production of stromelysin and tissue inhibitor of metalloproteinase-1 (TIMP-1) in bovine articular chondrocytes. Biomed. Res., 1992, 13, 343-8.
76. Nonaka, T.; Kikuchi, H.; Ikeda, T.; Okamoto, Y.; Hamanishi, C.; Tanaka, S. Hyaluronic acid inhibits the expression of u-PA, PAI-1, and u-PAR in human synovial fibroblasts of osteoarthritis and rheumatoid arthritis. J. Rheumatol., 2000, 27, 997-1004.
77. Nonaka, T.; Kikuchi, H.; Shimada, W.; Itagene, H.; Ikeda, T.; Hamanishi, C.; Tanaka, S. Effects of hyaluronic acid on fibrinolytic factors in the synovial fluid (in vivo). Pathophysiology, 1999, 6, 41-4.
78. Takahashi, K.; Hashimoto, S.; Kubo, T.; Hirasawa, Y.; Lotz, M.; Amiel, D. Hyaluronan suppressed nitric oxide production in the meniscus and synovium of rabbit osteoarthritis model. J. Orthop. Res., 2001, 19, 500-3.
79. Díaz-Gallego, L.; Prieto, J.G.; Coronel, P.; Gamazo, L.E.; Gimeno, M.; Álvarez, A.I. Apoptosis and nitric oxide in an experimental model of osteoarthritis in rabbit after hyaluronic acid treatment. J. Orthop. Res., 2005, 23, 1370-6.
80. Rockey, D.C.; Chung, J.J.; McKee, C.M.; Noble, P.W. Stimulation of inducible nitric oxide synthase in rat liver by hyaluronan fragments. Hepatology., 1998, 27, 86-92.
81. Yasuda, T. Hyaluronan inhibits cytokine production by lypopolysaccharide-stimulated U937 macrophages through down-regulation of NF-kappaB via ICAM-1. Inflamm. Res., 2007, 56, 246-53.
82. Campo, G.M.; Avenoso, A.; Campo, S.; D'Ascola, A.; Traina, P.; Samà, D.; Calatroni, A. Glycosaminoglycans modulate inflammation and apoptosis in LPS-treated chondrocytes. J. Cell Biochem., 2009, 106, 83-9.
83. Casalino-Matsuda, S.M.; Monzon, M.E.; Day, A.J.; Forteza, R.M. Hyaluronan fragments/CD44 mediate oxidative stress-induced MUC5B up-regulation in airway epithelium. Am. J. Respir. Cell Mol. Biol., 2009, 40, 277-85.
84. Ishida, O.; Tanaka, Y.; Morimoto, I.; Takigawa, M.; Eto, S. Chondrocytes are regulated by cellular adhesion through CD44 and hyaluronic acid pathway. J. Bone Miner. Res., 1997, 12, 1657-63.
85. Chow, G.; Nietfeld, J.J.; Knudson, C.B.; Knudson, W. Antisense inhibition of chondrocyte CD44 expression leading to cartilage chondrolysis. Arthritis Rheum., 1998, 41, 1411-9.
86. Knudson, W.; Loeser, R.F. CD44 and integrin matrix receptors participate in cartilage homeostasis. Cell Mol. Life Sci., 2002, 59, 36-44.
87. Andreadis, A.A.; Hazen, S.L.; Comhair, S.A.A.; Erzurum, S.C. Oxidative and nitrosative events in asthma. Free Radic. Biol. Med., 2003, 35, 213-25.
88. Teder, P.; Vandivier, R.W.; Jiang, D.H.; Liang, J.R.; Cohn, L.; Pure, E.; Henson, P.M.; Noble, P.W. Resolution of lung inflammation by CD44. Science, 2002, 296, 155-8.
89. Casalino-Matsuda, S.M.; Monzon, M.E.; Conner, G.E.; Salathe, M.; Forteza, R.M. Role of hyaluronan and reactive oxygen species in tissue kallikrein-mediated epidermal growth factor receptor activation in human airways. J. Biol. Chem., 2004, 279, 21606-16.
90. Fattman, C.L.; Schaefer, L.M.; Oury, T.D. Extracellular superoxide dismutase in biology and medicine. Free Radic. Biol. Med., 2003, 35, 236-56.
91. Manzanares, D.; Monzon, M.E.; Savani, R.C.; Salathe, M. Apical oxidative hyaluronan degradation stimulates airway ciliary beating via RHAMM and RON. Am. J. Respir. Cell Mol. Biol., 2007, 37, 160-8.
92. Bartold, P.M.; Page, R.C. The effect of chronic inflammation on gingival connective. J. Oral Pathol., 1986, 15, 367-74.
93. Di Paola, R.; Mazzon, E.; Rotondo, F.; Dattola, F.; Britti, D.; De Majo, M.; Genovese, T.; Cuzzocrea, S. Reduced development of experimental periodontitis by treatment with M40403, a superoxide dismutase mimetic. Eur. J. Pharmacol., 2005, 516, 151-7.
94. Yevdokimova, N.Y. Elevated level of ambient glucose stimulates the synthesis of high-molecular-weight hyaluronic acid by human mesangial cells. The involvement of transforming growth factor beta1 and its activation by thrombospondin. Acta. Biochim. Pol., 2006, 53, 383-93.
95. Bot, P.T.; Hoefer, I.E.; Piek, J.J.; Pasterkamp, G. Hyaluronic acid: targeting immune modulatory components of the extracellular matrix in atherosclerosis. Curr. Med. Chem., 2008, 15, 786-91.
96. Schimizzi, A.L.; Massie, J.B.; Murphy, M.; Perry, A.; Kim, C.W.; Garfin, S.R.; Akeson, W.H. High-molecular-weight hyaluronan inhibits macrophage proliferation and cytokine release in the early wound of a preclinical postlaminectomy rat model. Spine J., 2006, 6, 550-6.
97. Mjaatvedt, C.H.; Yamamura, H.; Capehart, A.A.; Turner, D.; Markwald, R.R. The Cspg2 gene, disrupted in the hdf mutant, is required for right cardiac chamber and endocardial cushion formation. Dev. Biol., 1998, 202, 56-66.
98. Rooney, P.; Kumar, S.; Ponting, J.; Wang, M. The role of hyaluronan in tumour neovascularization. Int. J. Cancer, 1995, 60, 632-6.
99. Sattar, A.; Rooney, P.; Kumar, S.; Pye, D.; West, D.C.; Scott, I.; Ledger, P. Application of angiogenic oligosaccharides of hyaluronan increase blood-vessel numbers in skin. J. Invest. Dermatol., 1994, 103, 576-9.
100. Slevin, M.; Krupinski, J.; Gaffney, J.; Matou, S.; West, D.; Delisser, H.; Savani, R.C.; Kumar, S. HA-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol., 2007, 26, 58-68.
101. Heldin, P.; Karousou, E.; Bernert, B.; Porsch, H.; Nishitsuka, K.; Skandalis, S.S. Importance of HA-CD44 interactions in inflammation and tumorigenesis. Connect. Tissue Res., 2008, 49, 215-8.
102. Weigel P.H. . In Chemistry and Biology of Hyaluronan; Elsevier Ltd, Amsterdam, 2004; pp. 553-567.
103. Adamia, S.; Reiman, T.; Crainie, M.; Mant, M.J.; Belch, A.R.; Pilarski, L.M. Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma. Blood, 2005, 105, 4836-44.
104. Simpson, M.A.; Wilson, C.M.; McCarthy, J.B. Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am. J. Pathol., 2002, 161, 849-57.